However, the reported Aβ-targeted trials in AD patients to date have not been successful, addressing the need to test alternative therapeutic approaches beyond Aβ focusing on other key early events, including synaptic dysfunction, hyperphosphorylation and aggregation of tau or the initial steps of neuroinflammation. Here, MAPT is linked to Alzheimer disease.